Jonathan M. Gerber, MD, PhD

Click here to read the Cover Story, “Reimbursement remains ‘difficult issue’ in CAR T-cell therapy rollout.”

Recent developments in the management of acute myeloid leukemia, including the FLT3 inhibitor midostaurin, have led to advances for a patient population that has not seen new agents in many years, according to Jonathan M. Gerber, MD, of the Carolinas HealthCare System’s Levine Cancer Institute.

Patients with chronic myeloid leukemia who achieve a sustained deep molecular response for more than 1 year can safely discontinue second-line or maintenance dasatinib treatment, according to phase 2 study results.

ORLANDO, Fla. — The addition of midostaurin to standard chemotherapy, followed by 1 year of maintenance therapy, significantly improved EFS and OS for patients with newly diagnosed acute myeloid leukemia and FLT3 mutations, according to phase 3 study results presented at the ASH Annual Meeting and Exposition.

Single-agent azacitidine improved survival for older patients with newly diagnosed acute myeloid leukemia, according to results from a randomized open-label phase 3 trial.

The presence of NPM1 mutations without FLT3-internal tandem duplication was associated with favorable prognosis in patients with acute myeloid leukemia aged 55 to 65 years, according to study findings.

Chimeric antigen receptor-modified T cells that target CD19 induced complete remissions in 90% of pediatric and adult patients with relapsed and refractory acute lymphoblastic leukemia, according to study results.

Patients with myelodysplastic syndrome who harbored TP53, TET2 or DNMT3A mutations demonstrated significantly shorter OS after allogeneic hematopoietic stem-cell transplantation, according to study results.